Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02026921

A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer

Ovarian Epithelial Cancer Recurrent Clinical Trial

Official title:
A Phase II Study of Docetaxel and Carboplatin as Second Line Chemotherapy in First Relapse of Platinum Sensitive Epithelial Ovarian Cancer

Clinical Trial Summary

A phase II single arm study of carboplatin and docetaxel in treatment of first sensitive relapse of epithelial ovarian, peritoneal or tubal cancer.

Hypothesis: Treatment with this combination in second line is safe and with a low frequency of neurologic side effect.

Clinical Trial Description

Evaluation of toxicity and response of treatment with carboplatin and docetaxel to patients with epithelial cancer of ovary, fallopian tube or peritoneum with their first relapse occurring at least 6 months after end of first line treatment- Evaluation of toxicity according to Clinical Toxicity Criteria version 2. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

  • Neoplasms, Glandular and Epithelial
  • Ovarian Epithelial Cancer Recurrent
  • Ovarian Neoplasms
Clinical Trial Details
NCT number NCT02026921
Study type Interventional
Source Nordic Society for Gynaecologic Oncology
Contact
Status Completed
Phase Phase 2
Start date June 2004
Completion date December 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT01899599 - PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Phase 2
Active, not recruiting NCT01715168 - A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer Phase 1
Completed NCT02394015 - Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Completed NCT01588964 - IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer Phase 2
Completed NCT02260544 - Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Phase 1
Completed NCT01735071 - Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer Phase 2
Active, not recruiting NCT01611766 - Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Phase 3
Completed NCT02735928 - Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor N/A
Completed NCT02014337 - Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Phase 1
Active, not recruiting NCT01376752 - Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment Phase 3